Multicenter phase II clinical trial of gemcitabine and cisplatin as neoadjuvant chemotherapy for patients with high-grade upper tract urothelial carcinoma Journal Article
| Authors: | Coleman, J. A.; Yip, W.; Wong, N. C.; Sjoberg, D. D.; Bochner, B. H.; Dalbagni, G.; Donat, S. M.; Herr, H. W.; Cha, E. K.; Donahue, T. F.; Pietzak, E. J.; Hakimi, A. A.; Kim, K.; Al-Ahmadie, H. A.; Vargas, H. A.; Alvim, R. G.; Ghafoor, S.; Benfante, N. E.; Meraney, A. M.; Shichman, S. J.; Kamradt, J. M.; Nair, S. G.; Baccala, A. A. Jr; Palyca, P.; Lash, B. W.; Rizvi, M. A.; Swanson, S. K.; Muina, A. F.; Apolo, A. B.; Iyer, G.; Rosenberg, J. E.; Teo, M. Y.; Bajorin, D. F. |
| Article Title: | Multicenter phase II clinical trial of gemcitabine and cisplatin as neoadjuvant chemotherapy for patients with high-grade upper tract urothelial carcinoma |
| Abstract: | PURPOSENeoadjuvant chemotherapy (NAC) has proven survival benefits for patients with invasive urothelial carcinoma of the bladder, yet its role for upper tract urothelial carcinoma (UTUC) remains undefined. We conducted a multicenter, single-arm, phase II trial of NAC with gemcitabine and split-dose cisplatin (GC) for patients with high-risk UTUC before extirpative surgery to evaluate response, survival, and tolerability.METHODSEligible patients with defined criteria for high-risk localized UTUC received four cycles of split-dose GC before surgical resection and lymph node dissection. The primary study end point was rate of pathologic response (defined as < ypT2N0). Secondary end points included progression-free survival (PFS), overall survival (OS), and safety and tolerability.RESULTSAmong 57 patients evaluated, 36 (63%) demonstrated pathologic response (95% CI, 49 to 76). A complete pathologic response (ypT0N0) was noted in 11 patients (19%). Fifty-one patients (89%) tolerated at least three complete cycles of split-dose GC, 27 patients (47%) tolerated four complete cycles, and all patients proceeded to surgery. With a median follow up of 3.1 years, 2- and 5-year PFS rates were 89% (95% CI, 81 to 98) and 72% (95% CI, 59 to 87), while 2- and 5-year OS rates were 93% (95% CI, 86 to 100) and 79% (95% CI, 67 to 94), respectively. Pathologic complete and partial responses were associated with improved PFS and OS compared with nonresponders (≥ ypT2N any; 2-year PFS 100% and 95% v 76%, P <.001; 2-year OS 100% and 100% v 80%, P <.001).CONCLUSIONNAC with split-dose GC for high-risk UTUC is a well-tolerated, effective therapy demonstrating evidence of pathologic response that is associated with favorable survival outcomes. Given that these survival outcomes are superior to historical series, these data support the use of NAC as a standard of care for high-risk UTUC, and split-dose GC is a viable option for NAC. © American Society of Clinical Oncology. |
| Keywords: | clinical trial; cisplatin; gemcitabine; neoadjuvant therapy; phase 2 clinical trial; bladder tumor; urinary bladder neoplasms; multicenter study; carcinoma, transitional cell; transitional cell carcinoma; humans; human |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 8 |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-03-10 |
| Start Page: | 1618 |
| End Page: | 1625 |
| Language: | English |
| DOI: | 10.1200/jco.22.00763 |
| PROVIDER: | scopus |
| PMCID: | PMC10043554 |
| PUBMED: | 36603175 |
| DOI/URL: | |
| Notes: | MSK Cancer Center Support Grant (P30 CA008748) acknowledged in PubMed and PDF -- MSK corresponding author is Jonathan Coleman -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work